Benchmark analyst Nathan Martin maintains CSX (NASDAQ:CSX) with a Buy and lowers the price target from $36 to $35.
Benchmark Maintains Buy on CSX, Lowers Price Target to $35
Benchmark analyst Nathan Martin maintains CSX (NASDAQ:CSX) with a Buy and lowers the price target from $36 to $35.
Related Posts
‘Senator seeks FTC probe of data sales to U.S. government agencies’ -Washington Post Report
https://www.washingtonpost.com/technology/2022/12/15/wyden-ftc-neustar-sussmann/
Safety Shot Responds To FSD Pharma’s Unauthorized Tagging Of Its Stock And Making False Claims In An Effort To Harm The Company And Its Shareholders
Safety Shot is Not GBB Drink Lab, Inc. (GBB) and never acquired GBB as falsely claimed by FSD Pharma; Only the Safety Shot beverage asset was acquired; The lawsuit referred to by FSD Pharma is with GBB only GBB
Quince Therapeutics Updates Pipeline Progress, Eyes Enrollment for Pivotal Phase 3 Trial in Ataxia-Telangiectasia, Reported Q1 EPS Loss of $(0.26), Cash Balance of $67.8M
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today